Lipo-CvsPemvidutide

Lipo-C is a multi-component lipotropic formulation where each ingredient targets a different aspect of fat metabolism. The MIC complex (methionine, inositol, choline) forms the core. Methionine is an essential amino acid that serves as a methyl donor and precursor to S-adenosyl methionine (SAM), which is required for the methylation of phospholipids in the liver — a process critical for packaging and exporting triglycerides as VLDL particles. Without adequate methionine, fat accumulates in hepatocytes.

Inositol, specifically myo-inositol, functions as a second messenger in insulin signaling pathways and is involved in phospholipid synthesis. It enhances insulin sensitivity at the cellular level and plays a role in serotonin receptor function, which may help regulate appetite and mood during caloric restriction. Choline is the precursor to phosphatidylcholine, the primary phospholipid component of cell membranes and lipoprotein particles. Choline deficiency directly causes hepatic steatosis (fatty liver) because the liver cannot package and export triglycerides without sufficient phosphatidylcholine.

The formulation is typically augmented with vitamin B12 (cyanocobalamin or methylcobalamin), which is a cofactor for methionine synthase and required for proper methylation cycle function, and L-carnitine, which transports long-chain fatty acids across the inner mitochondrial membrane for beta-oxidation. Together, the components support hepatic fat processing, mitochondrial fat burning, and the metabolic methylation pathways that connect them. The clinical evidence for MIC injections specifically is limited, though the biochemical rationale for each individual component in fat metabolism is well-established.

Pemvidutide (ALT-801) is a once-weekly subcutaneous dual GLP-1 and glucagon receptor agonist, mechanistically similar to mazdutide and survodutide but with a distinct molecular design and a primary development focus on metabolic dysfunction-associated steatohepatitis (MASH) alongside obesity. The dual mechanism combines appetite suppression with enhanced energy expenditure and direct hepatic fat mobilisation.

The GLP-1 receptor component drives the established central appetite suppression through hypothalamic and brainstem signalling, slows gastric emptying, and stimulates glucose-dependent insulin secretion. The glucagon receptor agonism component is what differentiates pemvidutide from pure GLP-1 drugs — glucagon binding in hepatocytes activates adenylyl cyclase and protein kinase A, driving up fatty acid beta-oxidation and ketogenesis while reducing de novo lipogenesis. This directly mobilises stored hepatic triglycerides for energy use rather than continued storage, addressing the core pathology of MASH. In adipose tissue and beyond, glucagon signalling also raises whole-body energy expenditure through thermogenic and futile-cycle mechanisms.

The receptor potency ratio is balanced so that glucagon-driven hepatic glucose output is offset by GLP-1-driven insulinotropic effects, yielding net glycemic improvement alongside enhanced fat oxidation. Phase 2b results in obesity demonstrated approximately 15.6% mean body weight loss at 48 weeks, and parallel MASH trials showed significant reductions in liver fat content alongside improvements in fibrosis markers. Phase 3 trials in both obesity and MASH are now underway, positioning pemvidutide as Altimmune's lead asset and a competitor to mazdutide and survodutide in the dual GLP-1/glucagon class.